InspireMD (NSPR) 10-K 19 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 18, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	1,433,607
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Public Float			$ 1,603,155
Entity Common Stock, Shares Outstanding		41,888,895
Trading symbol	NSPR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 9,384	$ 3,710
Accounts receivable:
Trade, net	716	643
Other	104	207
Prepaid expenses	81	62
Inventory	1,134	533
TOTAL CURRENT ASSETS	11,419	5,155
NON-CURRENT ASSETS:
Property, plant and equipment, net	421	476
Fund in respect of employee rights upon retirement	448	476
TOTAL NON-CURRENT ASSETS	869	952
TOTAL ASSETS	12,288	6,107
Accounts payable and accruals:
Trade	929	328
Other	1,966	2,134
Contract liability	25	20
TOTAL CURRENT LIABILITIES	2,920	2,482
LONG-TERM LIABILITIES-
Liability for employees rights upon retirement	605	624
TOTAL LONG-TERM LIABILITIES	605	624
COMMITMENTS AND CONTINGENT LIABILITIES (Note 9)
TOTAL LIABILITIES	3,525	3,106
REDEEMABLE PREFERRED SHARES		274
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2018 and 2017; 38,408,953 and 1,483,808 shares issued and outstanding at December 31, 2018 and 2017, respectively	4
Preferred stock value
Additional paid-in capital	156,351	143,079
Accumulated deficit	(147,592)	(140,352)
Total equity	8,763	2,727
Total liabilities, redeemable preferred shares and equity	12,288	6,107
Series B Preferred Stock [Member]
EQUITY:
Preferred stock value
Series C Preferred Stock [Member]
EQUITY:
Preferred stock value
Series D Preferred Stock [Member]
EQUITY:
Preferred stock value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	38,408,953	1,483,556
Common stock, shares outstanding	38,408,953	1,483,556
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	17,303	27,075
Preferred stock, shares outstanding	17,303	27,075
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	61,423	741,651
Preferred stock, shares outstanding	61,423	741,651
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	750	750
Preferred stock, shares issued	0	750
Preferred stock, shares outstanding	0	750

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUES	$ 3,601	$ 2,761
COST OF REVENUES	2,606	2,176
GROSS PROFIT	995	585
OPERATING EXPENSES:
Research and development	1,535	1,276
Selling and marketing	2,241	2,357
General and administrative	4,830	5,184
Total operating expenses	8,606	8,817
LOSS FROM OPERATIONS	(7,611)	(8,232)
FINANCIAL EXPENSES, net:
Interest expenses		119
Other financial expenses (income)	(371)	60
Total financial expenses (income)	(371)	179
LOSS BEFORE TAX EXPENSES	(7,240)	(8,411)
TAX EXPENSES		27
NET LOSS	(7,240)	(8,438)
BASIC AND DILUTED LOSS PER SHARE:
Beneficial conversion feature of series C preferred shares		(633)
Extinguishment and accretion of preferred shares	(456)	(3,957)
NET LOSS APPLICABLE TO ORDINARY SHARES	$ (7,696)	$ (13,028)
NET LOSS PER SHARE - basic and diluted	$ (0.33)	$ (34.98)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	23,076,944	372,460

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Series B Convertible Preferred Stock [Member]		Series C Convertible Preferred Stock [Member]		Series D Preferred Stock [Member]		Total
Balance at Dec. 31, 2016		[1]	$ 135,959	$ (131,914)		[1]					$ 4,045
Balance, shares at Dec. 31, 2016	42,401				311,521
Net loss				(8,438)							(8,438)
Issuance of Preferred shares and warrants, net of $776 issuance costs			$ 6,072					[1]			$ 6,072
Issuance of Preferred shares and warrants, net of $776 issuance costs, shares							1,069,822
Issuance of preferred shares, net of $90 issuance costs			$ 660							[1]	$ 660
Issuance of preferred shares, net of $90 issuance costs, shares									750
Conversion of Series B Convertible Preferred Stock to common shares		[1]	$ 660			[1]					$ 660
Conversion of Series B Convertible Preferred Stock to common shares, shares	1,404,424				(284,446)
Conversion of Series C Convertible Preferred Stock to common shares		[1]						[1]				[1]
Conversion of Series C Convertible Preferred Stock to common shares, shares	37,506						(328,171)
Classification of Redemption Obligation of preferred shares holder to Mezzanine			$ (934)								$ (934)
Share-based compensation related to restricted stock award, net of forfeitures of shares		[1]	333								333
Share-based compensation related to restricted stock award, net of forfeitures of shares, shares	(118)
Share-based compensation related to stock options award			339								339
Taxes withheld in respect of share issuance		[1]	$ (10)								$ (10)
Taxes withheld in respect of share issuance, shares	(657)
Balance at Dec. 31, 2017		[1]	$ 143,079	$ (140,352)		[1]		[1]		[1]	$ 2,727
Balance, shares at Dec. 31, 2017	1,483,556				27,075		741,651		750
Net loss				(7,240)							(7,240)
Conversion of Series B Convertible Preferred Stock to common shares		[1]	274			[1]					274
Conversion of Series B Convertible Preferred Stock to common shares, shares	80,620				(9,772)
Conversion of Series C Convertible Preferred Stock to common shares		[1]	936					[1]			936
Conversion of Series C Convertible Preferred Stock to common shares, shares	1,144,726						(326,436)
Classification of Redemption Obligation of preferred shares holder to Mezzanine											620
Share-based compensation related to restricted stock award, net of forfeitures of shares		[1]	70								70
Share-based compensation related to restricted stock award, net of forfeitures of shares, shares	(201)
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,206 issuance costs	$ 4		15,823								15,827
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,206 issuance costs shares	35,588,810				442,424		1,069,822
Redemption of Series D Preferred Stock			(750)							[1]	(750)
Redemption of Series D Preferred Stock, shares									(750)
Classification of Series C Convertible Preferred Stock			(3,200)					[1]			(3,200)
Classification of Series C Convertible Preferred Stock, shares							(353,792)
Exercise of Unit Purchase Option		[1]	$ 557								557
Exercise of Unit Purchase Option, shares	111,442
Accretion of redeemable preferred shares			$ (438)								(438)
Balance at Dec. 31, 2018	$ 4		$ 156,351	$ (147,592)		[1]		[1]		[1]	$ 8,763
Balance, shares at Dec. 31, 2018	38,408,953				17,303		61,423
[1]	Represents an amount less than $1 thousand

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Issuance costs	$ 2,206	$ 776
Restricted stock award, shares	201	202
Represents equity value, description	Represents an amount less than $1 thousand
Preferred C Stock [Member]
Issuance costs		$ 776
Preferred D Stock [Member]
Issuance costs		$ 90
Common Stock [Member]
Issuance costs	$ 2,206

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,240)	$ (8,438)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	152	178
Loss from sale of property, plant and equipment		8
Change in liability for employees rights upon retirement	(19)	(37)
Financial income and interest paid	(392)
Share-based compensation expenses	70	672
Loss (gains) on amounts funded in respect of employee rights upon retirement, net	5	(17)
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses	(19)	3
Increase in trade receivables	(73)	(287)
Decrease (increase) in other receivables	90	(37)
Increase in inventory	(601)	(33)
(Decrease) increase in trade payables	584	(290)
(Decrease) increase in other payables and contract liability	(163)	584
Net cash used in operating activities	(7,606)	(8,131)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(67)	(258)
Amounts funded (withdrawn) in respect of employee rights upon retirement, net	23	(60)
Net cash used in investing activities	(44)	(318)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares and warrants and exercise of Pre-Funded Warrants and unit purchase option, net of $2,206 and $776 issuance costs, respectively	16,384	6,822
Redemption of series C and D preferred stock	(3,014)
Repayment of long-term loan		(2,179)
Taxes withheld in respect of share issuance		(10)
Net cash provided by financing activities	13,370	4,633
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(46)	10
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5,674	(3,806)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	3,710	7,516
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	9,384	3,710
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Income taxes
Interest paid		583
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:
Issuance Costs		90
Classification of Redemption Obligation of Preferred Shares to Mezzanine and Embedded Derivative, see Note 10a	$ 164	$ 274

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Issuance costs	$ 2,206	$ 776

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s coronary product combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company markets its products through distributors in international markets, mainly in Europe and Latin America. b. Liquidity The Company has an accumulated deficit as of December 31, 2018, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™ EPS) reach commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company has sufficient resources to fund operations through the end of the third quarter of 2019. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, classification and fair value of financial instruments and legal contingencies. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”. f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. i. Revenue recognition Revenue recognition following the adoption of the New Revenue Standard on January 1, 2018 On January 1, 2018, the Company adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all the related amendments (the “New Revenue Standard”) to all contracts using the modified retrospective method. The standard did not have any effect upon its initial application. A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment, legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13. Revenue recognition prior to the adoption of the New Revenue Standard on January 1, 2018 Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title, fixed or determinable and risks and rewards for the products are transferred to the customer and collection is reasonably assured. The Company recognizes revenue net of value added tax (VAT). j. Research and development costs Research and development costs are charged to the statement of operations as incurred. k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are market and performance based and dependent upon achieving certain goals. With respect to performance-based awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest. l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”. m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $157,000 and $193,000 for the years ended December 31, 2018 and 2017, respectively. o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock (after adding the beneficial conversion feature included in the Series C Convertible Preferred Stock and the extinguishment of Series B Convertible Preferred Stock and the extinguishment and accretion of Series D and Series C Convertible Preferred shares) by the weighted average number of shares of common stock outstanding during the period, including 1,081,581 and 23,481 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock for the years ended December 31, 2018 and 2017, respectively (since they are convertible based on passage of time). The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, restricted stocks, preferred stock and placement agent unit as their effect is anti-dilutive. p. Segment reporting The Company has one operating and reportable segment. q. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. r. Issued accounting pronouncements 1) In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company has determined the adoption will not have a material impact on its consolidated financial statements. 2) In February 2016, the FASB issued ASU 2016-02 Leases. The guidance establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The guidance will become effective for interim and annual periods beginning on January 1, 2019. a modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company expects to adopt the new standard on January 1, 2019 and use the effective date as its date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company expects that this standard will have a material effect on its’s financial statements. The most significant effect relates to the recognition of new ROU assets and lease liabilities on the balance sheet for its operating leases of real estate and vehicles; and (2) providing significant new disclosures about the Company’s leasing activities. The Company, however, does not expect a material impact to its consolidated statements of income and consolidated statements of cash flow. On adoption, the Company currently expects to recognize additional operating liabilities of approximately $1.1 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term lease recognition exemption for all leases that qualify. This means, for those leases, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease components for all of the Company’s leases. 3) Fair Value Measurement (Topic 820) In August 2018, the FASB issued ASU 2018-13—Fair value measurement (Topic 820)—Disclosure framework—Changes to the disclosure requirements for fair value measurement. This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Certain disclosures required by this guidance will need to be applied on a retrospective basis and others on a prospective basis. The guidance will be effective for fiscal years beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 4) Financial Instruments-Credit Losses (Topic 326) In June 2016, the FASB issued Accounting Standards Update No. 2016-13 (ASU 2016-13) “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. We will adopt ASU 2016-13 effective January 1, 2020. We are currently evaluating the effect of the adoption of ASU 2016-13 on our consolidated financial statements.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 3 - FAIR VALUE MEASURMENT The following tables summarize the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs: Derivative Liability ($ in thousands) Balance as of January 1, 2017 $ - Classification of Redemption Obligation of preferred shares holder to Mezzanine 66 Conversion of Series B Convertible Preferred Stock to common shares (66 ) Balance as of December 31, 2017 - Classification of Redemption Obligation of preferred shares holder to Mezzanine 620 Conversion of Series C Convertible Preferred Stock to common shares (182 ) Revaluation of embedded derivative- financial income (438 ) Balance as of December 31, 2018 $ - Level 3 liabilities include Derivative Liability related to the Company Series B Convertible Preferred Stock and Series C Convertible Preferred Stock, as described in Note 10. The Company values the Level 3 Derivative Liability using multi-period Binomial model, whose inputs include probability of completing fund raising and the related fund raise amounts, volatility of stock prices, stock prices, term to extinguish the Series C Convertible Preferred shares held by the Series D investor (se defined in Note 10). In calculating the fair value of Derivative Liability related to the Series C Convertible Preferred Stock, the Company used the following assumptions: stock price of $4.20 for the transaction date, and Volatility of 140.95% -166.60% for the transaction date. Regarding the derivative embedded in Series B redeemable preferred stock, which is a Level 3 measurement, see Note 10a.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	NOTE 4 - PROPERTY, PLANT AND EQUIPMENT a. December 31, 2018 2017 ($ in thousands) Cost: Computer equipment $ 241 $ 214 Office furniture and equipment 73 75 Machinery and equipment 1,262 1,209 Leasehold improvements 144 143 1,720 1,641 Less - accumulated depreciation and amortization (1,299 ) (1,165 ) Net carrying amount $ 421 $ 476 b. Depreciation and amortization expenses totaled approximately $139,000 and $153,000 for the years ended December 31, 2018 and 2017, respectively.

Liability for Employees Right U

Liability for Employees Right Upon Retirement	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Liability for Employees Right Upon Retirement	NOTE 5 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses were approximately $186,000 and $154,000 for the years ended December 31, 2018 and 2017, respectively. Defined contribution plan expenses were approximately $244,000 and $223,000 for the years ended December 31, 2018 and 2017, respectively. The Company expects contribution plan expenses in 2019 to be approximately $241,000.

Loan

Loan	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Loan	NOTE 6 - loan During the year ended 2017, the Company paid the remaining interest and principal balances under a Loan and Security Agreement from October 23, 2013, in consideration of $2,684,000. Principal payments of $2,179,000 were classified as financing cash outflows in the consolidated statement of cash flows, with the remaining interest payment classified within operating cash flows. All liens and other security interests granted by the Company and its subsidiaries in connection with the Loan and Security Agreement were terminated upon such payment.

Related Parties Transactions

Related Parties Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Parties Transactions	NOTE 7 - RELATED PARTIES TRANSACTIONS a. Chief Executive Officer (“CEO”) On September 5, 2017 the Company and the Company’s CEO entered into a fifth amendment (the “Fifth Amendment”) to the CEO’s employment agreement, in order to, among other things (i) modify the term of the CEO’s employment to (a) continue until July 31, 2018, and (b) provide that in the event that the term is not extended beyond July 31, 2018, by mutual agreement of the parties and the Company does not offer the CEO a position as CEO on the same or more favorable terms with an annual base salary of at least $400,000, the CEO’s termination will be deemed a termination without cause; and (ii) amend the terms and conditions of the CEO’s compensation, as described below. Pursuant to the Fifth Amendment, the CEO was to be paid a base salary of no less than $30,416.67 per month ($365,000 on an annualized basis) while he was employed by the Company during the term; such amount may be reduced only as part of an overall cost reduction program that affects all of the senior executives of the Company and does not disproportionately affect the CEO, so long as such reductions do not reduce the base salary to a rate that is less than 90% of the amount set forth above (or 90% of the amount to which it has been increased). Notwithstanding the foregoing, in the event of the closing of a transaction or series of related transactions with investors where Company raises an aggregate of $7 million from such investors, the CEO’s annual base salary would increase to $400,000. The CEO’s annual base salary was increased to $400,000, as the March 2018 and the April 2018 offerings raised more than $7 million, effective as of April 1, 2018 with payment beginning as of the first November 2018 pay period. During the year ended 2018, including after the expiration of the term on July 31, 2018, the CEO’s compensation was paid pursuant to the prior employment agreement, as amended by the fifth amendment, until, on February 4, 2019, the Company entered into an amended and restated employment agreement (the “A&R Employment Agreement”) with the CEO, which amended, restated and superseded the CEO’s prior employment agreement. Pursuant to the prior employment agreement, as amended by the Fifth Amendment, the CEO was eligible to receive, subject to the CEO’s continued employment through the applicable grant date, (i) a nonqualified stock option relating to the number of shares of the Company’s common stock equal to 2% of the Company’s outstanding common stock on the date of the closing of the Financing (the “Financing Option”) and (ii) an award of a number of restricted shares of the Company’s common stock equal to 2% of our outstanding common stock on the date of the closing of the Financing (the “Financing Restricted Stock Award” and together with the Financing Option, the “Financing Equity Grant”), in each case, subject to the availability of shares for grant under the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “2013 Plan”). The CEO has an option to deliver a number of shares with an aggregate fair market value that equals or exceeds (to avoid issuance of fractional shares) the required tax withholding payment resulted from the vesting of the restricted stock or from the exercise of the options. As of December 31, 2018 and 2017, 0 and 657 shares were withheld by the Company to satisfy tax withholding obligations, respectively. The payment, amounting to $0 and $10,000, respectively, was deducted from equity. b. c. d. During the years ended December 31, 2018 and 2017, the Company did not grant any stock options to directors and executive officers. e. Balances with related parties: December 31, 2018 2017 ($ in thousands) Current liabilities: Other accounts payable $ 44 $ 47 f . Transactions with related parties: Year ended December 31, 2018 2017 ($ in thousands) Compensation expenses (including share-based compensation) $ 830 $ 1,208

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net Loss Per Share	NOTE 8 - NET LOSS PER SHARE: Set forth below is data taken into account in the computation of loss per share: December 31, 2018 2017 ($ in thousands expect share and share data) Net Loss $ (7,240 ) $ (8,438 ) Beneficial conversion feature of Series C Convertible Preferred shares (633 ) Extinguishment and accretion of Series D and Series C Convertible Preferred shares (456 ) Extinguishment of Series B Convertible Preferred shares (3,957 ) Adjusted Loss $ (7,696 ) $ (13,028 ) Weighted average of Ordinary Shares outstanding during the period 23,076,944 372,460 Basic and diluted loss per share (dollars) $ (0.33 ) $ (34.98 ) The total number of shares of common stock related to outstanding options, warrants, restricted stock, Series C Convertible Preferred Stock, Series D Convertible Preferred Stock and placement agent units excluded from the calculations of diluted loss per share were 44,045,612 and 510,823 for the years ended December 31, 2018 and 2017, respectively.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 9 - COMMITMENTS AND CONTINGENT LIABILITIES a. Lease commitments: 1) The Subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement. Rent expense included in the consolidated statements of operations totaled approximately $330,000 and $379,000 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements are as follows: ($ in thousands) Year Ended December 31: 2019 $ 300 2020 300 $ 600 2) The Company leases its motor vehicles under operating lease agreements. As of December 31, 2018, the aggregate non-cancelable future minimum lease obligations for motor vehicles were approximately $7,000. b. Litigation: The Company received written communication from a distributor to provide unspecified compensation for pre-paid goods subject to the voluntary field action (from April 2014). After considering the views of its legal counsel as well as other factors, the Company’s management believes that there is a reasonably possible likelihood of a loss from any related future proceedings would range from a minimal amount up to 1,075,000 Euros. On April 26, 2016 the Company received a suit seeking damages from the Company amounting to $2.2 million in cash and unspecified compensation in equity in connection with certain finders’ fees. By Order dated February 23, 2017, the U.S. District Court for the Southern District of New York granted our motion to dismiss the suit in its entirety. On January 23, 2018, the clerk entered judgment dismissing the complaint consistent with the District court’s order. The Claimants have not appealed the District Court’s judgement, and the time in which to do so has expired. Accordingly, this matter is now closed. In July 2016, a service provider filed a suit seeking damages from the Company’s subsidiary amounting to $1,967,822. The Company’s management, after considering the views of its legal counsel as well as other factors, is of the opinion that a loss to the Company is neither probable nor in an amount or range of loss that is estimable.

Equity

Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Equity	NOTE 10 - EQUITY a. Share capital The Company’s common shares are listed on the NYSE American. On February 7, 2018, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-thirty-five reverse stock split of its common stock, par value $0.0001 per share, effective as of February 7, 2018, which decreased the number of issued and outstanding shares of common stock and restricted shares of common stock as of December 31, 2017 from 51.9 million shares to 1.5 million shares. All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. Status of Share Capital as of December 31, 2018 During 2018 and 2017, the Company made multiple transactions related to the capital structure. Following either redemption or conversion of the company’s preferred stock, as of December 31, 2018, the Company has 17,303 shares of Series B Convertible Preferred Stock outstanding (convertible into 3,330,828 shares of common stock) out of 442,424 shares originally issued, 61,423 shares of Series C Convertible Preferred Stock (convertible into 1,310,357 shares of common stock) out of 1,069,822 shares originally issued and no Series D Convertible Preferred Stock. The respective certificate of designation for our Series B Convertible Preferred Stock and Series C Convertible Preferred Stock contains a full ratchet anti-dilution price protection to be triggered upon issuance of equity or equity-linked securities at an effective common stock purchase price of less than the conversion price in effect, so the number of shares of common stock issuable upon conversion of the Series B or C Convertible Preferred Stock could increase if another equity financing is completed at a price lower than the current conversion price of $0.30 per share. Series B Convertible Preferred Stock – The July 2016 Offering On July 7, 2016, the Company closed a public offering of 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants (which is referred to as the “Series A Warrants”) to purchase up to 50,620 shares of common stock (the “July 2016 Offering”). Each share of Series B Convertible Preferred Stock and the accompanying Series A Warrants were sold at a price of $33.00. Each share of Series B Convertible Preferred Stock was initially convertible into 0.114 shares of common stock, reflecting a conversion price equal to $288.75 per share. The Series B Convertible Preferred Stock has certain anti-dilution provisions, and as further described below, in accordance with such provisions, the conversion price for the Series B Convertible Preferred Stock was adjusted several times when the Company conducted subsequent equity financings, and as of December 31, 2018, each share of Series B Convertible Preferred Stock is convertible into 110 shares of common stock at $0.30 per share. The holders of Series B Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion. The Series B Convertible Preferred Stock will automatically convert into shares of common stock after five years from issuance. Additionally, holders of the Series B Convertible Preferred Stock may elect to convert at any time. As further described below, the certificate of designation for the Series B Convertible Preferred Stock was amended in December 2017 to provide for an automatic exchange of each share of Series B Convertible Preferred Stock upon consummation of an offering of our common stock or common stock equivalents for gross proceeds of at least $8 million (a “Qualified Offering”) subject to the beneficial ownership limitation. The Series B Convertible Preferred Stock is subject to provisions providing for make-whole payments, pursuant to which, if the Series B Convertible Preferred Stock is converted into shares of common stock at any time prior to the fifth anniversary of the date of issuance, the holders will receive all of the dividends that, but for the early conversion, would have otherwise accrued on the applicable shares of Series B Convertible Preferred Stock being converted for the period commencing on the conversion date and ending on the fifth anniversary of the date of issuance, less the amount of all prior dividends paid on such converted Series B Convertible Preferred Stock before the date of conversion. The Series A Warrants are exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $175.00 per share of common stock. The Company received gross proceeds of approximately $14.6 million from the July 2016 Offering, before deducting placement agent fees and offering expenses payable by the Company. In connection with the closing of the offering of the Series B Convertible Preferred Stock and Series A Warrants, the Company issued to the placement agent a unit purchase option to purchase a number of our securities equal to an aggregate of 3.5% of the securities sold in the July 2016 Offering. The placement agent unit purchase option has an exercise price equal to 125% of the public offering price. For accounting purposes, the Company analyzed the classification of the Series B Convertible Preferred Stock, including whether the embedded conversion options should be bifurcated. As the Series B Convertible Preferred Stock is not redeemable, and the host contract was determined to be akin to equity, the entire instrument was classified as equity. The Company has also concluded that the warrants accompanying Series B Convertible Preferred Stock are classified as equity, since the warrants meet all criteria for equity classification. Series C Convertible Preferred Stock – The March 2017 Offering On March 14, 2017, the Company closed a public offering of 1,069,822 shares of Series C Convertible Preferred Stock, Series B warrants to purchase up to 122,269 shares of common stock and Series C warrants to purchase up to 122,269 shares of common stock (the “March 2017 Offering”). Each share of Series C Convertible Preferred Stock and the accompanying warrants were sold at a price of $6.40. Each share of Series C Convertible Preferred Stock was initially convertible into 0.114 shares of common stock reflecting a conversion price equal to $56.00 per share. The Series C Convertible Preferred Stock has certain anti-dilution provisions, and as further described below, in accordance with such provisions, the conversion price for the Series C Convertible Preferred Stock was adjusted several times when the Company conducted subsequent equity financings, and as of December 31, 2018, each share of Series C Convertible Preferred Stock is convertible into 1,310,357 shares of common stock at $0.30 per share. The Company received gross proceeds of approximately $6.8 million from the March 2017 Offering, before deducting placement agent fees payable by the Company equal to 8.0% of the gross proceeds of the offering and a solicitation fee equal to 3.0% of the proceeds from the exercise of the Series C Warrants and offering expenses payable by the Company. The holders of Series C Convertible Preferred Stock may elect to convert at any time. The Series C Convertible Preferred Stock has certain anti-dilution provisions which provisions require the lowering of the applicable conversion price, as then in effect, to the purchase price of equity or equity-linked securities issued in subsequent offerings which will result in a greater number of shares of common stock being required to be issued to the holders of Series C Convertible Preferred Stock The Series B warrants are exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $70.00 per share of common stock. The Series C warrants expired on September 14, 2017, and none were exercised prior to their expiration. For accounting purposes, the Company analyzed the classification of the Series C Convertible Preferred Stock, including whether the embedded conversion options should be bifurcated. As the Series C Convertible Preferred Stock is not redeemable, and the host contract was determined to be akin to equity, the entire instrument was classified as equity. The Company has also concluded that the warrants accompanying Series C Convertible Preferred Stock are classified as equity, since the warrants meet all criteria for equity classification. Pursuant to the terms of the July 2016 Offering that provided the holders of the Series B Convertible Preferred Stock with certain anti-dilution provisions, which provisions require the lowering of the applicable conversion price, as then in effect, to match the purchase price of equity or equity-linked securities issued in subsequent offerings, upon closing of the March 2017 Offering, the conversion price of the Series B Convertible Preferred Stock was adjusted to $56.00 per share of common stock, and each share of Series B Convertible Preferred Stock became convertible into 0.589 shares of common stock. As a result of such adjustment, the Company was required to issue to the holders of the Series B Convertible Preferred Stock an aggregate of 258,952 additional shares of common stock upon conversion of the Series B Convertible Preferred Stock and as payment of the dividends thereunder in common stock, based on 311,521 shares of Series B Convertible Preferred Stock outstanding as of March 8, 2017. Series D Convertible Preferred Stock and amendments to existing preferred stock through December 31, 2017 in connection with the Series D Private Placement On December 1, 2017, as part of a planned recapitalization, the Company sold 750 shares of Series D Convertible Preferred Stock (“Series D Preferred Stock”) to an institutional investor (“Series D Investor”) in a private placement pursuant to a securities purchase agreement (the “SPA”), dated November 28, 2017, for aggregate gross proceeds of $750,000. The stated value of each share of Series D Preferred Stock was $1,000, and each share of Series D Preferred Stock was initially convertible into 142.86 shares of common stock at $7.00 per share. The Series D Preferred Stock did not contain any substantive features that differ materially from common stock other than a mechanism that would prevent the Company from issuing, upon conversion of the Series D Preferred Stock into common stock, a number of shares of common stock which would exceed 42,677 shares (19.99% of the number of shares of common stock outstanding on the trading day immediately preceding the date of the SPA) of the Company common stock, unless the Company obtains shareholders’ approval required by the NYSE American. In addition, the SPA contained a “most favored nation” provision, which provided that, until the Company consummates a “Qualified Offering”, in the event the Company undertakes, or enter into any agreement to undertake, the issuance and sale of common stock and/or common stock equivalents to third party investors for cash (a “Subsequent Financing”), the Series D Investor may elect, in its sole discretion, to exchange all or some of the Series D Preferred Stock then held by such investor for any securities or units issued in such Subsequent Financing on a $1.00 per stated value for $1.00 new subscription amount basis (the “Series D Exchange Right”) . The surrender of Series D Preferred Stock was to be in lieu of any cash subscription amount required for the participation in such Subsequent Financing. The Series D Investor also had the option to exchange their Series D Preferred Stock into the securities issued in a Qualified Offering upon consummation of a Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis. As a result of the issuance and sale of the Series D Preferred Stock, the conversion price of the outstanding shares of Series B Convertible Preferred Stock was reduced to $7.00 pursuant to the anti-dilution adjustment provisions of the Series B Convertible Preferred Stock, and the number of shares the Company would be required to issue to the holders of the Series B Convertible Preferred Stock upon conversion of the Series B Convertible Preferred Stock and as payment of the dividends thereunder in common stock was increased by an aggregate of 1,306,536 shares of common stock, based on 180,992 shares of Series B Convertible Preferred Stock outstanding as of November 28, 2017. There was no change to the conversion price of our outstanding Series C Convertible Preferred Stock as a result of an amendment made to the terms of the Series C Convertible Preferred Stock exempting the issuance of the Series D Preferred Stock from the anti-dilution adjustment provisions of the Series C Convertible Preferred Stock The Company also agreed to use 12.5% of the proceeds from any subsequent offering of the Company’s securities to redeem the outstanding shares of Series B Convertible Preferred Stock owned by the Series D Investor until such time that the Company has redeemed, in the aggregate, at least $1 million of Series B Convertible Preferred Stock, up to $1.5 million of stated value of Series B Convertible Preferred Stock (“Redemption Obligation of Series B”). In addition, in accordance with the original SPA, the certificate of designation for the Series B Convertible Preferred Stock was amended in December 2017 to provide for an automatic exchange of each share of Series B Convertible Preferred Stock upon the consummation of a Qualified Offering subject to the beneficial ownership limitation. Furthermore, the original SPA provided that, upon the consummation of a Qualified Offering, the shares of Series C Convertible Preferred Stock owned by the Series D Investor would be automatically exchanged into the securities sold by the Company in a Qualified Offering upon the terms set forth in the Agreement. However, under the rules of the NYSE American, the Company was required to obtain shareholder approval for the exchange by such purchaser of any securities in the Qualified Offering that represent 20% or more of the Company’s total shares of common stock outstanding immediately prior to such offering. For accounting purposes, the Company analyzed the classification of the Series D Preferred Stock, including whether the embedded conversion options should be bifurcated. As the Series D Preferred Stock is not redeemable, and the host contract was determined to be akin to equity, the entire instrument was classified as equity. As of the date of the SPA, the Company analyzed the classification of the Redemption Obligation of Series B of the Company regarding the Series B Convertible Preferred Stock as agreed upon in the SPA. Based on ASC 480-10-S99 the Company determined that, as of the date of the SPA, since the Redemption Obligation of Series B was outside of its control, the Series B Convertible Preferred Stock was considered as contingently redeemable upon the occurrence of an event that is outside of its control and should be classified as a mezzanine equity. The Company determined that, as of the date of the SPA, Subsequent Financing and the related payment of Redemption Obligation of Series B was considered to be outside of the Company’s control. Accordingly, as of the date of the SPA, the redemption amount net of the embedded derivative (as described below), which amounts to $934,000, was classified as “Redeemable Preferred Shares” in the Consolidated Balance Sheet. In addition, as of the date of the SPA, the Company analyzed whether the conversion feature embedded in the shares of the Series B Convertible Preferred Stock subject to the Redemption Obligation of Series B should be bifurcated. As certain shares of the Series B Convertible Preferred Stock was contingently redeemable as of the date of the SPA, the host contract was determined to be akin to debt, and the other criteria under ASC 815-15-25-1 were met, an embedded derivative was separated from the host contract and accounted for as a derivative instrument pursuant to Subtopic 815-10. As of the date of the SPA, the embedded derivative was valued at $66,000. Furthermore, as of the date of the SPA, the Company analyzed whether the change in the conversion price of the Series B Convertible Preferred Stock constituted an extinguishment for accounting purpose, by comparing the fair value of such preferred stock immediately before and after such change in terms. Since the fair value increased substantially, i.e by more than 10%, the change in terms was accounted for as an extinguishment. As a result, the difference between the fair value of the preferred stock immediately after the change in term and the carrying amount immediately before such change, in the amount of approximately $3.9 million, was added to the basic loss per share attributable to the Company’s ordinary stockholders in the year ended December 31, 2017. Conversion of Series B Convertible Preferred Stock held by Series D Investor Of the 284,446 shares of Series B Convertible Preferred Stock that were converted during the year ended December 31, 2017, 206,105 shares were converted by the Series D Investor, and as of December 31, 2017, the Series D Investor held 8,295 shares Series B Convertible Preferred Stock with a stated value of $274,000. Accordingly, the maximum Redemption Obligation of Series B amount as of December 31, 2017, was $274,000. In addition, following the conversions of Series B Convertible Preferred Stock during the year ended December 31, 2017, the value of the embedded derivative as of December 31, 2017, was $0. On January 8, 2018, the Series D Investor converted its remaining 8,295 shares Series B Convertible Preferred Stock. Accordingly, following such conversions, the Company was no longer required to redeem any shares of Series B Convertible Preferred Stock held by the Series D Investor upon closing of a Subsequent Financing and the maximum Redemption Obligation of Series B was reduced to $0. Placement Agent Unit Purchase Option Exercise and Series B Convertible Preferred Stock Conversion During January and February 2018, the placement agent from the July 2016 Offering exercised its unit purchase option to purchase 13,508 units and received 13,508 shares of Series B Convertible Preferred Stock and 1,545 Series A warrants to purchase common stock. The placement agent subsequently converted its Series B Convertible Preferred Stock and received an aggregate of 111,443 shares of common stock. The Company received an aggregate of $557,205 from the placement agent for the exercise of the unit purchase option. Series D Amendments and 2018 Equity Offerings On February 21, 2018, the SPA was amended (“February 2018 SPA amendment”) to require the Company (i) to use 15% of the proceeds from any subsequent offering of the Company’s securities that is not a Qualified Offering to redeem the outstanding shares of the Series C Convertible Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series C Convertible Preferred Stock, and (ii) upon closing of any subsequent offering that is a Qualified Offering, to exchange all remaining outstanding shares of Series C Convertible Preferred Stock held by the Series D Investor for any securities issued in such Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis (subject to the beneficial ownership limitation set forth in the certificate of designation for the Series C Convertible Preferred Stock). The February 2018 SPA amendment provided that in the event that the Company fails, or is unable, to issue securities issued in the Qualified Offering to the Series D Investor in exchange for such investor’s remaining Series C Convertible Preferred Stock due to limitations mandated by the NYSE American, the Securities and Exchange Commission, or for any other reason, the Company would be required to offer to purchase from such investor those shares of Series C Convertible Preferred Stock not exchanged for the securities sold in the Qualified Offering at a per share purchase price equal to the stated value of Series C Convertible Preferred Stock. This requirement to purchase from the Series D Investor those shares of Series C Convertible Preferred Stock not exchanged for the securities sold in the Qualified Offering at a per share purchase price equal to the stated value of Series C Convertible Preferred Stock in case of a Qualified Offering, and the requirement to use 15% of the proceeds from any subsequent offering of the Company’s securities that is not a Qualified Offering to redeem the outstanding shares of the Series C Convertible Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series C Convertible Preferred Stock are referred to as “Redemption Obligation of Series C.” For accounting purposes, as of the effective date of the February 2018 SPA amendment, the Company analyzed the classification of the Series C Convertible Preferred Stock in light of the Redemption Obligation of Series C regarding such preferred stock held by the Series D Investor, as agreed upon in the February 2018 SPA amendment. Based on ASC 480-10-S99 the Company determined that since the Redemption Obligation of Series C may occur upon contingent events, such as subsequent financing transactions not meeting the threshold for a Qualified Offering, that are not solely within the Company’s control, as of the effective date of the February 2018 SPA amendment the Series C Convertible Preferred Stock was considered as contingently redeemable and should be classified outside of permanent equity, within mezzanine equity. In addition, as of the effective date of the February 2018 SPA amendment, the Company analyzed whether the conversion feature embedded in the shares of the Series C Convertible Preferred Stock subject to the Redemption Obligation of Series C should be bifurcated. As certain shares of the Series C Convertible Preferred Stock were contingently redeemable, as of the effective date of the February 2018 SPA amendment, the host contract was determined to be akin to debt, and the conversion feature not clearly and closely to the debt host given the anti-dilution protection included in the terms of these Series C Convertible Preferred Stock. Consequently, an embedded derivative was separated from the host contract and accounted for as a derivative instrument pursuant to Subtopic 815-10. As of the effective date of the February 2018 SPA amendment, the Company classified an amount of $3,200,000 from permanent equity to “Redeemable Preferred Shares” and “Derivative Liability” in an amount of $2,580,000 and $620,000, respectively. The Company values Level 3 derivative liability using an internally developed valuation model, whose inputs include potential equity transactions probability of completing successful fund raising during the relevant period and stock prices. On February 26, 2018, the Company and the Series D Investor entered into a waiver agreement (the “Waiver Agreement”) which provided that (i) the Series D Exchange Right, which was provided by the original SPA, would not be applicable to an offering of up to $7,000,000 which occurred no later than March 9, 2018, (ii) the Company shall reduce the conversion price of the Series D Preferred Stock to the public offering price of our common stock in such offering, and (iii) instead of using 15% of the proceeds from such offering to redeem shares of Series C Convertible Preferred Stock held by the Series D Investor, which was provided by the February 2018 SPA amendment, the Company was required to use 15% of the proceeds from such offering to redeem a portion of the outstanding shares of Series D Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series D Preferred Stock. On March 1, 2018, the Company closed an underwritten public offering of 1,000,000 shares (the “March 2018 Offering”) of the Company’s common stock. The offering price to the public of the shares sold at the March 2018 Offering was $3.00 per share. The Company received gross proceeds of $3.0 million from the offering, before deducting underwriter commissions and discounts and other fees and expenses payable by the Company .In connection with the March 2018 Offering, the Company issued to the underwriter warrants to purchase up to 60,000 shares of common stock, or 6% of the number of shares of common stock sold in the offering (the “March Underwriter Warrants”). The March Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending February 27, 2023, at a price per share equal to $3.75 (125% of the offering price to the public per share). Pursuant to the SPA, as amended by February 2018 SPA amendment and the Waiver Agreement, following the closing of the offering on March 1, 2018, the Company used $450,000 (representing 15% of the gross proceeds from the March 2018 Offering) to purchase from the Series D Investor 450 shares of the Series D Preferred Stock at a per share purchase price equal to the stated value of the Series D Preferred Stock. As a result of the March 2018 Offering, the respective conversion price for each of the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Preferred Stock was reduced to $3.00 per share, and the number of shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Preferred Stock had increased as follows: ● an aggregate of 190,333 additional shares of common stock upon conversion of the Series B Convertible Preferred Stock and as payment of the dividends thereunder in common stock, based on 17,303 shares of Series B Convertible Preferred Stock outstanding as of March 1, 2018. ● an aggregate of 1,497,427 additional shares of common stock upon conversion of the Series C Convertible Preferred Stock, based on 741,651 shares of Series C Convertible Preferred Stock outstanding as of March 1, 2018. ● an aggregate of 142,857 additional shares of common stock upon conversion of the Series D Preferred Stock, based on 750 shares of Series D Preferred Stock outstanding as of March 1, 2018. For accounting purposes, as of the closing of the March 2018 Offering, the Company analyzed whether the change in the conversion price of the Series D Preferred Stock constitutes an extinguishment for accounting purposes, by comparing the fair value of the Series D Preferred Stock immediately before and after such change in terms. Since the fair value increased substantially, i.e by more than 10%, the change in terms was accounted for as an extinguishment. As a result, the difference between the fair value of the Series D Preferred Stock immediately after the change in term (the reduction of the conversion price from $7.00 per share to $3.00 per share, pursuant to the SPA, as amended by February 2018 SPA amendment and the Waiver Agreement) and the carrying amount immediately before such change, in the amount of $49,000, was added to the basic loss per share attributable to the Company’s common stockholders. On March 28, 2018, the Company and the Series D Investor entered into the second waiver agreement (the “Second Waiver Agreement”) which provided that (i) the Series D Exchange Right, which was provided by the original SPA, would not be applicable to a subsequent financing consisting solely of shares of common stock, which shall be publicly registered on Form S-3 for gross proceeds to us of up to $5,000,000, to be consummated by not later than April 3, 2018 (the “Planned April 2018 Offering”), (ii) the Company’s obligation to use 15% of the proceeds from any subsequent offering of our securities that is not a Qualified Offering to redeem the outstanding shares of the Series C Convertible Preferred Stock held by the Series D Investor, which was provided by the February 2018 SPA amendment, would not be applicable to the Planned April 2018 Offering, (iii) the Company shall reduce the conversion price of the Series D Preferred Stock to the public offering price of our common stock sold in the Planned April 2018 Offering, and (iv) the Company shall use $300,000 of the proceeds from the Planned April 2018 Offering to redeem outstanding shares of Series C Convertible Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series C Convertible Preferred Stock. On April 2, 2018, the Company closed an underwritten public offering of 2,857,143 shares (the “April 2018 Offering”) of the Company’s common stock at the offering price to the public of $1.75 per share. The Company received gross proceeds of $5.0 million from the offering, before deducting underwriter discounts and commissions and other fees and expenses payable by the Company. In connection with the April 2018 Offering, the Company agreed to issue to the underwriter warrants to purchase up to 171,429 shares of common stock, or 6% of the April 2, 2018 Shares sold in the offering (the “April Underwriter Warrants”). The April Underwriter Warrants will be exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending March 28, 2023, at a price per share equal to $2.1875 (125% of the offering price to the public in the April 2018 Offering). Pursuant to the SPA, as amended by the February 2018 SPA amendment, the Waiver Agreement and the Second Waiver Agreement, following the closing of the April 2018 Offering, the Company used $300,000 of the net proceeds of the offering to purchase from the Series D Investor 46,875 shares of the Series C Convertible Preferred Stock at a per share purchase price equal to the stated value of the Series C Convertible Preferred Stock. As a result of the April 2018 Offering, the conversion price of the outstanding shares of Series D Preferred Stock was reduced to $1.75 pursuant to the Second Waiver Agreement, and the number of shares of common stock issuable upon conversion of the Series D Preferred Stock increased by an aggregate of 71,429 additional shares of common stock, based on 300 shares of Series D Preferred Stock outstanding as of April 2, 2018. For accounting purposes, as of the closing of the April 2018 Offering, the Company analyzed whether the change in the conversion price of the Series D Preferred Stock constituted an extinguishment for accounting purposes, by comparing the fair value of the Series D Preferred Stock immediately before and after such change in terms. Since the fair value increased substantially, i.e by more than 10%, the change in terms was accounted for as an extinguishment. As a result, the difference between the fair value of the Series D Preferred Stock immediately after the change in term (the further reduction of the conversion price from $3.00 per share to $1.75 per share, pursuant to the SPA, as amended by February 2018 SPA amendment, the Waiver Agreement and the Second Waiver Agreement) and the carrying amount immediately before such change, in the amount of $32,000, was subtracted from the basic loss per share attributable to the Company’s common stockholders. Upon execution of the underwriting agreement for the April 2018 Offering, as of March 28, 2018, the respective conversion price of the outstanding shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock was reduced to $1.75 pursuant to the anti-dilution adjustment provisions of the Series B Convertible Preferred Stock and of the Series C Convertible Preferred Stock, and the number of shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock had increased as follows: ● an aggregate of 237,916 additional shares of common stock upon conversion of the Series B Convertible Preferred Stock and as payment of the dividends thereunder in common stock, based on 17,303 shares of Series B Convertible Preferred Stock outstanding as of March 28, 2018. ● an aggregate of 688,297 additional shares of common stock upon conversion of the Series C Convertible Preferred Stock, based on 451,695 shares of Series C Convertible Preferred Stock outstanding as of March 28, 2018. On June 28, 2018, the Company and the Series D Investor entered into a letter agreement (the “Letter Agreement”)

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Taxes on Income	NOTE 11 - TAXES ON INCOME: a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2018 is 21%. State tax may also apply. Taxation in Israel In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate in 2016 and thereafter, from 26.5% to 25%. In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. The corporate tax rate was 23% in 2018 and will be 23% thereafter. Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%. b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five to eight years of a reduced tax rate of 10% to 23% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all tax offsetting losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and eight years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2007, as a year of election and 2011 as an additional year of election. In the event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, the Company will be required to pay tax at a rate of 10% to 23% on the amount distributed, subject to certain conditions. In addition, dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 20% withholding tax. Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 1) Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled, and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest and linkage. The Company opted not to apply for Preferred Enterprise status (as defined in the Amendment of the Law for the Encouragement of Capital Investments, 1959). c. Carry forward tax losses As of December 31, 2018, the Company had a net carry forward tax loss of approximately $40 million, of which approximately $36 million (arising before January 1, 2018), expires until 2037, and approximately $4 million, which does not expire, but is limited to offset 80% of the net income in the year it is utilized. Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period. As of December 31, 2018, InspireMD Ltd. had a net carry forward tax loss of approximately $71 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely. d. Loss before income taxes The components of loss before income taxes are as follows: Year ended December 31 2018 2017 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (2,884 ) $ (3,673 ) Subsidiaries (4,356 ) (4,738 ) $ (7,240 ) $ (8,411 ) e. Current taxes on income The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the change in subsidiary tax rates and the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits and changes in tax rates following the 2017 Act. The changes in the valuation allowance for the year ended December 31, 2018 and 2017 were as follows: Year ended December 31 2018 2017 ($ in thousands) Balance at the beginning of the year $ 27,240 $ 29,682 Changes during the year: Changes following enactment of the Act (5,879 ) Losses during the year (including foreign exchange rate effect) 400 3,437 Balance at the end of the year $ 27,640 $ 27,240 f. Accounting for Uncertain Tax position Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2018: Year ended December 31, 2018 2017 ($ in thousands) Balance at beginning of period $ 28 $ - Increase in uncertain tax positions because of tax positions taken during the year - 28 Balance at end of period $ 28 $ 28 A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2015-2018 Israel 2014-2018 Germany 2013-2018 United Kingdom 2014-2015 g. Deferred income tax: December 31, 2018 2017 ($ in thousands) Long-term: Allowance for doubtful accounts 3 3 Allowance for bonus - 54 Provision for vacation and recreation pay 38 37 R&D expenses 339 289 Share-based compensation 2,581 2,577 Carry forward tax losses 24,643 24,245 Accrued severance pay, net 36 35 27,640 27,240 Less-valuation allowance (27,640 ) (27,240 ) $ - $ -

Supplementary Financial Stateme

Supplementary Financial Statement Information	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplementary Financial Statement Information	NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: a. Accounts receivable: The changes in “Allowance for doubtful accounts” during the years ended December 31, 2018 and 2017 are as follows: Year ended December 31, 2018 2017 ($ in thousands) Balance at beginning of period $ 72 $ 336 Additions during the period - - Bad debt written-off during the period - (270 ) Exchange rate differences - 6 Balance at end of period $ 72 $ 72 b. Inventories: December 31, 2018 2017 ($ in thousands) Finished goods $ 284 $ 174 Work in process 111 63 Raw materials and supplies 739 296 $ 1,134 $ 533 c. Accounts payable and accruals-other: December 31, 2018 2017 ($ in thousands) Employees and employee institutions $ 828 $ 853 Accrued vacation and recreation pay 171 165 Accrued expenses 903 976 Provision for sales commissions 37 109 Other 27 31 $ 1,966 $ 2,134

Disaggregated Revenue and Entit

Disaggregated Revenue and Entity Wide Disclosures	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Disaggregated Revenue and Entity Wide Disclosures	NOTE 13 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2018 2017 ($ in thousands) Germany $ 855 $ 551 Italy 632 557 Russia 351 343 Other 1,763 1,310 $ 3,601 $ 2,761 By product: Year ended December 31, 2018 2017 ($ in thousands) CGuard™ EPS $ 2,970 $ 1,922 MGuard Prime™ EPS 631 839 $ 3,601 $ 2,761 By principal customers: Year ended December 31, 2018 2017 Customer A 22 % 14 % Customer B 10 % 12 % Customer C 10 % 12 % All tangible long lived assets are located in Israel.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 - SUBSEQUENT EVENTS: On February 4, 2019, the Company and the Company’s CEO, entered into an amended and restated employment agreement (the “A&R Employment Agreement”). The A&R Employment Agreement amended, restated and superseded the CEO’s prior employment agreement with the Company, including any amendments thereto. The A&R Employment Agreement, among other things, (i) modify the term of the CEO’s employment to end on December 31, 2020 (“the A&R Term”), unless earlier terminated; (ii) grant the CEO 2,000,000 shares of restricted stock; (iii) upon achievement of certain criteria, the CEO will be eligible to receive an equity bonus relating to the number of shares of the Company’s common stock equal to 5% of the Company’s shares outstanding on the date of the grant (inclusive of, rather than in addition to, the 2,000,000 shares granted in (ii)), subject to Board approval, which shall be comprised of as close as is practicable to 50% stock options and 50% shares of restricted stock; (iv) entitle the CEO to a one-time lump sum severance payment of $850,000 if, during the A&R Term, the employment is terminated under certain conditions; provided, however, that if we have offered to extend the A&R Employment Agreement beyond December 31, 2020 on terms no less favorable than the terms of the A&R Employment Agreement and the CEO does not agree to such extension, the CEO will receive a one-time lump sum severance payment would be $600,000 instead of $850,000. In addition, as provided by the A&R Employment Agreement, in February 2019, we paid $33,000 to the CEO for his accrued but unused vacation time through the calendar year 2018. In February 2019, the Company granted 3,437,275 restricted shares to certain employees and directors, inclusive of the 2,000,000 restricted shares issued to the CEO as mentioned above.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, classification and fair value of financial instruments and legal contingencies.
Functional Currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of Consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and Cash Equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents.
Concentration of Credit Risk and Allowance for Doubtful Accounts	e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”.
Inventory	f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Property, Plant and Equipment	g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.
Impairment in Value of Long-lived Assets	h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.
Revenue Recognition	I. Revenue recognition Revenue recognition following the adoption of the New Revenue Standard on January 1, 2018 On January 1, 2018, the Company adopted the new accounting standard ASC 606, Revenue from Contracts with Customers, and all the related amendments (the “New Revenue Standard”) to all contracts using the modified retrospective method. The standard did not have any effect upon its initial application. A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment, legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13. Revenue recognition prior to the adoption of the New Revenue Standard on January 1, 2018 Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title, fixed or determinable and risks and rewards for the products are transferred to the customer and collection is reasonably assured. The Company recognizes revenue net of value added tax (VAT).
Research and Development Costs	j. Research and development costs Research and development costs are charged to the statement of operations as incurred.
Share-based Compensation	k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are market and performance based and dependent upon achieving certain goals. With respect to performance-based awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest.
Uncertain Tax Positions	l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”.
Deferred Income Taxes	m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.
Advertising	n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $157,000 and $193,000 for the years ended December 31, 2018 and 2017, respectively.
Net Loss Per Share	o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock (after adding the beneficial conversion feature included in the Series C Convertible Preferred Stock and the extinguishment of Series B Convertible Preferred Stock and the extinguishment and accretion of Series D and Series C Convertible Preferred shares) by the weighted average number of shares of common stock outstanding during the period, including 1,081,581 and 23,481 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock for the years ended December 31, 2018 and 2017, respectively (since they are convertible based on passage of time). The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, restricted stocks, preferred stock and placement agent unit as their effect is anti-dilutive.
Segment Reporting	p. Segment reporting The Company has one operating and reportable segment.
Fair Value Measurement	q. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Issued Accounting Pronouncements	r. Issued accounting pronouncements 1) In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company has determined the adoption will not have a material impact on its consolidated financial statements. 2) In February 2016, the FASB issued ASU 2016-02 Leases. The guidance establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The guidance will become effective for interim and annual periods beginning on January 1, 2019. a modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company expects to adopt the new standard on January 1, 2019 and use the effective date as its date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company expects that this standard will have a material effect on its’s financial statements. The most significant effect relates to the recognition of new ROU assets and lease liabilities on the balance sheet for its operating leases of real estate and vehicles; and (2) providing significant new disclosures about the Company’s leasing activities. The Company, however, does not expect a material impact to its consolidated statements of income and consolidated statements of cash flow. On adoption, the Company currently expects to recognize additional operating liabilities of approximately $1.1 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term lease recognition exemption for all leases that qualify. This means, for those leases, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease components for all of the Company’s leases. 3) Fair Value Measurement (Topic 820) In August 2018, the FASB issued ASU 2018-13—Fair value measurement (Topic 820)—Disclosure framework—Changes to the disclosure requirements for fair value measurement. This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Certain disclosures required by this guidance will need to be applied on a retrospective basis and others on a prospective basis. The guidance will be effective for fiscal years beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 4) Financial Instruments-Credit Losses (Topic 326) In June 2016, the FASB issued Accounting Standards Update No. 2016-13 (ASU 2016-13) “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. We will adopt ASU 2016-13 effective January 1, 2020. We are currently evaluating the effect of the adoption of ASU 2016-13 on our consolidated financial statements.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs: Derivative Liability ($ in thousands) Balance as of January 1, 2017 $ - Classification of Redemption Obligation of preferred shares holder to Mezzanine 66 Conversion of Series B Convertible Preferred Stock to common shares (66 ) Balance as of December 31, 2017 - Classification of Redemption Obligation of preferred shares holder to Mezzanine 620 Conversion of Series C Convertible Preferred Stock to common shares (182 ) Revaluation of embedded derivative- financial income (438 ) Balance as of December 31, 2018 $ -

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	a. December 31, 2018 2017 ($ in thousands) Cost: Computer equipment $ 241 $ 214 Office furniture and equipment 73 75 Machinery and equipment 1,262 1,209 Leasehold improvements 144 143 1,720 1,641 Less - accumulated depreciation and amortization (1,299 ) (1,165 ) Net carrying amount $ 421 $ 476

Related Parties Transactions (T

Related Parties Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Schedule of Balances with Related Parties	December 31, 2018 2017 ($ in thousands) Current liabilities: Other accounts payable $ 44 $ 47
Schedules of Transactions with Related Parties	Year ended December 31, 2018 2017 ($ in thousands) Compensation expenses (including share-based compensation) $ 830 $ 1,208

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Computation of Loss Per Share	Set forth below is data taken into account in the computation of loss per share: December 31, 2018 2017 ($ in thousands expect share and share data) Net Loss $ (7,240 ) $ (8,438 ) Beneficial conversion feature of Series C Convertible Preferred shares (633 ) Extinguishment and accretion of Series D and Series C Convertible Preferred shares (456 ) Extinguishment of Series B Convertible Preferred shares (3,957 ) Adjusted Loss $ (7,696 ) $ (13,028 ) Weighted average of Ordinary Shares outstanding during the period 23,076,944 372,460 Basic and diluted loss per share (dollars) $ (0.33 ) $ (34.98 )

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Obligations	As of December 31, 2018, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements are as follows: ($ in thousands) Year Ended December 31: 2019 $ 300 2020 300 $ 600

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of Convertible Preferred Shares	As of December 31, 2018, the Number of Preferred shares the amount each class is convertible into is below: Number of Preferred Stock Number of underlying Common stock Series B Convertible Preferred Stock 17,303 3,330,828 * Series C Convertible Preferred Stock 61,423 1,310,357 Total 4,641,185 * Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.
Schedule of Issuance of Warrants to Purchase Common Stock	As of December 31, 2018, the Company has outstanding warrants to purchase an aggregate of 40,746,189 shares of common stock as follows: Number of underlying Common stock Weighted average exercise price Series A Warrants 52,165 $ 175.00 Series B Warrants 122,269 $ 70.00 Series D Warrants 40,333,332 $ 0.30 Other warrants 238,423 $ 88.47 Total Warrants 40,746,189 $ 1.25
Schedule of Warrants and Share Options	The following table summarizes information about warrants and share options to employees: Year ended December 31 2018 2017 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 8,167 $ 970.55 9,655 $ 891.8 Granted - 118 32.2 Forfeited (1,808 ) 628.62 (1,606 ) 414.05 Exercised - - Outstanding -end of period 6,359 $ 1,158.55 8,167 $ 970.55 Exercisable at the end of the period 5,111 $ 1,414.42 5,295 $ 1,431.85 The following table summarizes information about warrants and share options to non-employees: Year ended December 31 2018 2017 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 49 $ 21,238.7 61 $ $31,164.7 Granted - - - - Forfeited (19 ) 12,417.53 (12 ) 58,165.8 Exercised - - - - Outstanding - end of period 30 32,348.23 49 $ 21,238.7 Exercisable at the end of the period 28 31,578.81 31 $ $ 20,874.35
Schedule of Information About Restricted Shares to Employees	The following table summarizes information about restricted shares to employees: Year ended December 31 2018 2017 Number of restricted shares Outstanding - beginning of period 1,093 3,755 Granted - 84 Forfeited (201 ) (202 ) Vested (486 ) (2,544 ) Outstanding - end of period 406 1,093
Schedule of Warrants and Options Outstanding and Exercisable	The following table provides additional information about all options outstanding and exercisable: Outstanding as of December 31, 2018 Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable $0-$65.1 127 7.68 48 $106.4-$113.75 3,003 7.92 2,002 $166.25-$437.5 3,051 7.56 2,883 $1,180-$19,512.5 86 6.54 86 $25,550-$73,500 122 2.6 119 6,389 7.62 5,138
Schedule of Assumptions Used in Fair Value of Options Granted to Employees	The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2017: Year ended December 31 2017 Expected life 5-6.5 years Risk-free interest rates 1.78%-2.18 % Volatility 94.42%-97.62 % Dividend yield 0 %
Schedule of Allocation of Total Share-based Compensation Expense	The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31 2018 2017 ($ in thousands) Cost of revenues $ 4 $ 7 Research and development - 32 Sales and marketing 6 86 General and administrative 60 547 $ 70 $ 672

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Loss Before Income Taxes	The components of loss before income taxes are as follows: Year ended December 31 2018 2017 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (2,884 ) $ (3,673 ) Subsidiaries (4,356 ) (4,738 ) $ (7,240 ) $ (8,411 )
Schedule of Changes in Valuation Allowance	The changes in the valuation allowance for the year ended December 31, 2018 and 2017 were as follows: Year ended December 31 2018 2017 ($ in thousands) Balance at the beginning of the year $ 27,240 $ 29,682 Changes during the year: Changes following enactment of the Act (5,879 ) Losses during the year (including foreign exchange rate effect) 400 3,437 Balance at the end of the year $ 27,640 $ 27,240
Schedule of Reconciliation of Uncertain Tax Positions	Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2018: Year ended December 31, 2018 2017 ($ in thousands) Balance at beginning of period $ 28 $ - Increase in uncertain tax positions because of tax positions taken during the year - 28 Balance at end of period $ 28 $ 28
Schedule of Open Tax Years by Major Jurisdiction	A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2015-2018 Israel 2014-2018 Germany 2013-2018 United Kingdom 2014-2015
Schedule of Deferred Income Tax	December 31, 2018 2017 ($ in thousands) Long-term: Allowance for doubtful accounts 3 3 Allowance for bonus - 54 Provision for vacation and recreation pay 38 37 R&D expenses 339 289 Share-based compensation 2,581 2,577 Carry forward tax losses 24,643 24,245 Accrued severance pay, net 36 35 27,640 27,240 Less-valuation allowance (27,640 ) (27,240 ) $ - $ -

Supplementary Financial State_2

Supplementary Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Allowance for Doubtful Accounts	The changes in “Allowance for doubtful accounts” during the years ended December 31, 2018 and 2017 are as follows: Year ended December 31, 2018 2017 ($ in thousands) Balance at beginning of period $ 72 $ 336 Additions during the period - - Bad debt written-off during the period - (270 ) Exchange rate differences - 6 Balance at end of period $ 72 $ 72
Schedule of Inventories	December 31, 2018 2017 ($ in thousands) Finished goods $ 284 $ 174 Work in process 111 63 Raw materials and supplies 739 296 $ 1,134 $ 533
Schedule of Accounts Payable and Accruals - Other	December 31, 2018 2017 ($ in thousands) Employees and employee institutions $ 828 $ 853 Accrued vacation and recreation pay 171 165 Accrued expenses 903 976 Provision for sales commissions 37 109 Other 27 31 $ 1,966 $ 2,134

Disaggregated Revenue and Ent_2

Disaggregated Revenue and Entity Wide Disclosures (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of Revenues Attributed to Geographic Areas	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2018 2017 ($ in thousands) Germany $ 855 $ 551 Italy 632 557 Russia 351 343 Other 1,763 1,310 $ 3,601 $ 2,761
Schedule of Revenues Attributed to Geographic Areas by Product	By product: Year ended December 31, 2018 2017 ($ in thousands) CGuard™ EPS $ 2,970 $ 1,922 MGuard Prime™ EPS 631 839 $ 3,601 $ 2,761
Schedule of Revenues Attributed to Geographic Areas by Principal Customers	By principal customers: Year ended December 31, 2018 2017 Customer A 22 % 14 % Customer B 10 % 12 % Customer C 10 % 12 %

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)Segmentshares	Dec. 31, 2017USD ($)shares
Description of methodology used for computing depreciation	Straight-line method
Description of uncertain tax benefits	Tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 157	$ 193
Weighted average shares common stock issuable | shares	23,076,944	372,460
Number of operating segment | Segment	1
Number of reportable segment | Segment	1
ASU 2016-02 [Member]
Additional operating liabilities | $	$ 1,100
Series B Preferred Stock [Member]
Weighted average shares common stock issuable | shares	1,081,581	23,481
Computers and Other Electronic Equipment [Member]
Estimated useful life	3 years
Office Furniture and Equipment [Member] | Minimum [Member]
Estimated useful life	7 years
Office Furniture and Equipment [Member] | Maximum [Member]
Estimated useful life	15 years
Machinery and Equipment [Member]
Estimated useful life	7 years

Fair Value Measurement (Details

Fair Value Measurement (Details Narrative) - Transaction Date [Member]	12 Months Ended
	Dec. 31, 2018$ / shares
Stock price	$ 4.20
Minimum [Member]
Volatility rate	140.95%
Maximum [Member]
Volatility rate	166.60%

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Fair Value of Financial Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Embedded Derivative, Beginning Balance
Classification of Redemption Obligation of preferred shares holder to Mezzanine	$ 620	(934)
Revaluation of embedded derivative- financial income	(438)
Embedded Derivative, Ending Balance
Series B Preferred Stock [Member]
Conversion of Preferred Stock to common shares		$ (66)
Series C Preferred Stock [Member]
Conversion of Preferred Stock to common shares	$ (182)

Property, Plant and Equipment_2

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 139	$ 153

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property plant and equipment, gross	$ 1,720	$ 1,641
Less - accumulated depreciation and amortization	(1,299)	(1,165)
Net carrying amount	421	476
Computer Equipment [Member]
Property plant and equipment, gross	241	214
Office Furniture and Equipment [Member]
Property plant and equipment, gross	73	75
Machinery and Equipment [Member]
Property plant and equipment, gross	1,262	1,209
Leasehold Improvements [Member]
Property plant and equipment, gross	$ 144	$ 143

Liability for Employees Right_2

Liability for Employees Right Upon Retirement (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Percentage of monthly deposits on salary	8.33%
Severance expenses	$ 186	$ 154
Defined contribution plan expense	244	$ 223
2019 [Member]
Defined contribution plan expense estimated	$ 241

Loan (Details Narrative)

Loan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Principal payments		$ 2,179,000
Loan and Security Agreement [Member]
Repayment of debt		2,684,000
Principal payments		$ 2,179,000

Related Parties Transactions (D

Related Parties Transactions (Details Narrative) - USD ($)	Sep. 05, 2017	Nov. 30, 2018	Apr. 30, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of restricted shares issued for tax withholding obligations, shares					0	657
Number of restricted shares issued for tax withholding obligations					$ 0	$ 10,000
Chief Executive Officer [Member]
Restricted common stock shares percentage					2.00%
Number of option granted
Director [Member]
Number of option granted
Chief Executive Officer [Member]
Number of option granted
Fifth Amendment Employment Agreement [Member]
Annual base and related expenses					$ 365,000
Base salary per month					$ 30,417
Fifth Amendment Employment Agreement [Member] | Maximum [Member]
Percentage of base salary					90.00%
Increase in salary			$ 400,000	$ 400,000	$ 400,000
Fifth Amendment Employment Agreement [Member] | Chief Executive Officer [Member]
Annual base and related expenses	$ 400,000
Fifth Amendment Employment Agreement [Member] | Investor [Member]
The amount needed to be raised by the Company		$ 7,000,000			$ 7,000,000

Related Parties Transactions -

Related Parties Transactions - Schedule of Balances with Related Parties (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Other accounts payable	$ 44	$ 47

Related Parties Transactions _2

Related Parties Transactions - Schedules of Transactions with Related Parties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Compensation expenses (including share-based compensation)	$ 830	$ 1,208

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Number of antidilutive securities excluded from computation of earnings per share	44,045,612	510,823

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net Loss	$ (7,240)	$ (8,438)
Beneficial conversion feature of series C preferred shares		(633)
Extinguishment and accretion of preferred shares	(456)	(3,957)
Adjusted loss	$ (7,696)	$ (13,028)
Weighted average of Common Stock and pre-funded warrants outstanding during the period	23,076,944	372,460
Basic and diluted loss per share (dollars)	$ (0.33)	$ (34.98)
Series D And C Preferred Stock [Member]
Extinguishment and accretion of preferred shares	$ (456)
Series B Preferred Stock [Member]
Net Loss
Extinguishment and accretion of preferred shares		$ (3,957)
Weighted average of Common Stock and pre-funded warrants outstanding during the period	1,081,581	23,481

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details Narrative)	Apr. 26, 2016USD ($)	Jul. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018EUR (€)
Lease expiration date			Dec. 31, 2020
Lease expiration date description			The Subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement.
Rent expenses			$ 330,000	$ 379,000
Future minimum lease obligations			600,000
Law suit seeking damages	$ 2,200,000
Former Service Provider [Member] | InspireMD GmbH [Member]
Law suit seeking damages		$ 1,967,822
Former Service Provider [Member] | Euro [Member]
Maximum amount of claim | €					€ 1,075,000
Motor Vehicles [Member]
Future minimum lease obligations			$ 7,000

Commitments and Contingent Li_4

Commitments and Contingent Liabilities - Schedule of Future Minimum Lease Obligations (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 300
2,020	300
Total	$ 600

Equity (Details Narrative)

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		Jul. 03, 2018	Jul. 02, 2018	Jun. 28, 2018	Apr. 02, 2018	Mar. 28, 2018	Mar. 02, 2018	Feb. 26, 2018	Feb. 21, 2018	Feb. 21, 2018	Feb. 07, 2018	Jan. 08, 2018	Dec. 02, 2017	Mar. 14, 2017	Mar. 08, 2017	Jul. 07, 2016	Mar. 28, 2011	Feb. 28, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Oct. 24, 2018	Jun. 29, 2018	Mar. 31, 2018	Nov. 28, 2017	Sep. 28, 2016	May 24, 2016	Sep. 09, 2015	Dec. 16, 2013
Common stock, par value																				$ 0.0001	$ 0.0001
Common stock, shares issued																				38,408,953	1,483,556
Common stock, shares outstanding																				38,408,953	1,483,556
Number of warrants to purchase common stock																				40,746,189
Conversion stock shares converted																				4,641,185
Warrant exercise price																				$ 1.25
Shares issued during the period new issue value																				$ 15,827
Fair value of embedded derivative													$ 66
Common stock shares authorized																				150,000,000	150,000,000
Accretion of the redeemable preferred shares																				$ (438)
Aggregate intrinsic value of the total exercisable warrants and options																				$ 1
Outstanding pre-funded warrants are exercisable into shares of common stock																				1,601,666
Capital stock shares authorized																				155,000,000
Capital stock par value																				$ 0.0001
Weighted average of the remaining contractual life																				7 years 6 months 25 days
Weighted average exercise price																					$ 24.85
Umbrella Plan [Member]
Stock option plan expiration date																	Mar. 27, 2021
Number of common stock awards reserve for future issuance																	572			310
Employee and Non-employee Stock Options [Member]
Weighted average of the remaining contractual life																				6 months 18 days
Unvested stock-based compensation																				$ 38
Chief Executive Officer [Member]
Stock option granted																				0	118
Exercise price range lower limit																				$ 24.85	$ 24.85
Exercise price range upper limit																				$ 34.65	$ 34.65
Stock option vesting period																				3 years	3 years
Fair value of stock option																				$ 3	$ 3
Chief Executive Officer [Member] | 2013 Plan [Member]
Number of common stock awards reserve for future issuance																				8,910,610									572
Stock option vested number of grant, shares																				8,919,737		8,900,000				7,200	11,428	537
Employees and Directors [Member]
Stock option granted																				0	118
Exercise price range lower limit																				$ 24.85	$ 24.85
Exercise price range upper limit																				$ 34.65	$ 34.65
Stock option vesting period																				3 years	3 years
Fair value of stock option																				$ 3	$ 3
Series D Purchase Agreement [Member]
Convertible preferred stock conversion price per share							$ 3
Sale of stock stated value per share, description									Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis (subject to the beneficial ownership limitation set forth in the certificate of designation for the Series C Preferred Stock).
Sale of stock, offering percentage									15.00%											15.00%
Series D Purchase Agreement [Member] | Series D Investor [Member]
Gross proceeds from offering, cost					$ 300
SPA Amendment [Member]
Shares issued during the period new issue value										$ 3,200
Fair value of embedded derivative									$ 620	620
Amount of redeemable preferred stock										$ 2,580
Waiver Agreement [Member] | Series D Investor [Member]
Gross proceeds from offering, cost								$ 7,000
Sale of stock, offering percentage								15.00%
Offering description								(i) the Series D Exchange Right would not be applicable to an offering of up to $7,000,000 which occurred no later than March 9, 2018, (ii) the Company shall reduce the conversion price of the Series D Preferred Stock to the public offering price of our common stock in such offering, and (iii) instead of using 15% of the proceeds from such offering to redeem shares of Series C Preferred Stock held by the Series D Investor, the Company shall use 15% of the proceeds from such offering to redeem a portion of the outstanding shares of Series D Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series D Preferred Stock.
Letter Agreement [Member]
Accretion of the redeemable preferred shares																			$ 438
Letter Agreement [Member] | Series D Investor [Member]
Sale of stock stated value per share, description				Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis, all outstanding shares of Series C Preferred Stock held by the Series D Investor will be redeemed at a per share purchase price equal to the stated value of the Series C Preferred Stock
Series A Warrants [Member]
Number of warrants to purchase common stock																		1,545
Common Stock [Member]
Shares issued during the period new issue							1,000,000													35,588,810
Gross proceeds from offering, cost							$ 3,000
Shares issued during the period new issue value																				$ 4
Stock issued price per shares																								$ 3
Accretion of the redeemable preferred shares
Number of redeemable preferred stock
Underwriter Warrants [Member]
Number of warrants to purchase common stock							60,000
Warrant exercise price							$ 3.75
Offering description							The Company issued to the underwriter warrants to purchase up to 60,000 shares of common stock, or 6% of the number of shares of common stock sold in the offering (the March Underwriter Warrants). The March Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending February 27, 2023, at a price per share equal to $3.75 (125% of the offering price to the public per share).
Percentage for shares of common stock sold					6.00%		6.00%
Percentage for gross proceeds of offering					125.00%		125.00%
Series D Warrants [Member]
Common units, per share																				$ 0.30
Pre-funded units, per share																				$ 0.30
Warrant [Member]
Shares issued during the period new issue																				20,880,250
Shares issued during the period new issue value																				$ 208,803
Exercise of pre-funded warrants																				20,880,250
Preferred Stock Blank Check [Member]
Preferred stock shares authorized																				5,000,000
Maximum [Member] | Underwriter Warrants [Member]
Number of warrants to purchase common stock					171,429
Stock issued price per shares					$ 2.1875
March 2017 Offering [Member]
Gross proceeds from offering, cost														$ 6,800
Gross proceeds from offering, cost percentage														8.00%
July 2016 Offering [Member]
Number of exercised options to purchase shares																		13,508
Public Offering [Member]
Shares issued during the period new issue					2,857,143
Gross proceeds from offering, cost					$ 5,000
Stock issued price per shares					$ 1.75
Qualified Offering [Member] | Series D Investor [Member]
Due from affiliates				$ 3,000
July 2018 Offering [Member]
Gross proceeds from offering, cost		$ 9,800
July 2018 Offering [Member] | Letter Agreement [Member]
Amount utilized for redemption of outstanding shares		$ 2,264,269
July 2018 Offering [Member] | Underwriting Agreement [Member]
Common stock, par value																							$ 0.0001
Number of warrants to purchase common stock																							4,999,999
Warrant exercise price																							$ 0.29
Common units, shares																							10,851,417
Pre-funded units, shares																							22,481,916
Common units, per share																							$ 0.30
Pre-funded units, per share																							0.29
Underwriting discount and commission price per shares																							$ 0.0203
July 2018 Offering [Member] | Common Stock [Member] | Underwriting Agreement [Member]
Number of warrants to purchase common stock																							4,999,999
July 2018 Offering [Member] | Underwriter Warrants [Member]
Stock issued price per shares		$ 0.375
Percentage for shares of common stock sold		6.00%
Percentage for gross proceeds of offering		125.00%
July 2018 Offering [Member] | Series D Warrants [Member] | Underwriting Agreement [Member]
Number of warrants to purchase common stock																							4,999,999
Underwriting discount and commission price per shares																							$ 0.0007
July 2018 Offering [Member] | Maximum [Member] | Underwriter Warrants [Member]
Number of warrants to purchase common stock		2,000,000
July 2018 Offering [Member] | Maximum [Member] | Series D Warrants [Member] | Underwriting Agreement [Member]
Common stock, par value																							$ 0.01
Number of warrants to purchase common stock																							4,999,999
Common stock shares authorized																							4,999,999
Secretary of State of Delaware a Certificate of Amendment [Member]
Reverse stock split											one-for-thirty-five reverse stock split.
Common stock, par value											$ 0.0001
Common stock, shares issued											51,900,000
Common stock, shares outstanding											1,500,000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding																				17,303
Convertible preferred stock shares issued upon conversion																				3,330,828	284,446
Shares issued during the period new issue																				442,424
Convertible preferred stock conversion price per share																				$ 0.30
Number of exercised options to purchase shares																		13,508
Proceeds from placement agent																		$ 557,205
Accretion of the redeemable preferred shares
Number of redeemable preferred stock
Series B Convertible Preferred Stock [Member] | Maximum [Member]
Convertible stock price, percentage																					10.00%
Series B Convertible Preferred Stock [Member] | July 2016 Offering [Member]
Preferred stock, shares outstanding															311,521
Shares issued during the period new issue															258,952
Convertible preferred stock conversion price per share														$ 56		$ 288.75				$ 0.30
Number of common stock shares sold																442,424
Number of warrants to purchase common stock																50,620
Share price																$ 33
Conversion stock shares converted														0.589		0.114				110
Percentage of cumulative dividend rate																				15.00%
Gross proceeds from offering, cost																$ 14,600					$ 8,000
Warrant exercise term																					5 years
Warrant exercise price																					$ 175
Option issued to purchase of shares percentage																3.50%
Option issued exercise price percentage																125.00%
Series B Convertible Preferred Stock [Member] | March 2017 Offering [Member]
Convertible preferred stock conversion price per share														$ 56
Series B Convertible Preferred Stock [Member] | Private Placements [Member]
Convertible preferred stock shares issued upon conversion													1,306,536												180,992
Convertible preferred stock conversion price per share													$ 7
Series C Convertible Preferred Stock [Member]
Preferred stock, shares outstanding																				61,423
Convertible preferred stock shares issued upon conversion																				1,310,357
Shares issued during the period new issue																				1,069,822
Convertible preferred stock conversion price per share																				$ 0.30
Accretion of the redeemable preferred shares
Number of redeemable preferred stock
Series C Convertible Preferred Stock [Member] | March 2017 Offering [Member]
Convertible preferred stock shares issued upon conversion																				1,310,357
Number of common stock shares sold														1,069,822
Share price																				$ 0.30
Conversion stock shares converted														0.114
Warrant exercise price														$ 6.40
Series D Convertible Preferred Stock [Member]
Preferred stock, shares outstanding
Convertible preferred stock shares issued upon conversion
Shares issued during the period new issue
Series D Convertible Preferred Stock [Member] | Redemption Obligation [Member]
Gross proceeds from offering, cost percentage													12.50%
Shares issued during the period new issue value													$ 1,000
Series D Convertible Preferred Stock [Member] | Redemption Obligation [Member] | Maximum [Member]
Shares issued during the period new issue value													$ 1,500
Series D Convertible Preferred Stock [Member] | Private Placements [Member]
Shares issued during the period new issue													750
Convertible preferred stock conversion price per share													$ 7
Conversion stock shares converted													142.86							42,677
Proceeds from sale of stock													$ 750
Shares issued during the period new issue value													$ 1
Common shares outstanding percentage													20.00%							19.99%
Sale of stock stated value per share, description																				In addition, the SPA contains a "most favored nation" provision, which provides that, until the Company consummates a "Qualified Offering", in the event the Company undertakes, or enter into any agreement to undertake, the issuance and sale of common stock and/or common stock equivalents to third party investors for cash (a "Subsequent Financing"), the Series D Investor may elect, in its sole discretion, to exchange all or some of the Series D Preferred Stock then held by such investor for any securities or units issued in such Subsequent Financing on a $1.00 per stated value for $1.00 new subscription amount basis (the "MFN Adjustment").
Series D Convertible Preferred Stock [Member] | Private Placements [Member] | Investor [Member]
Shares issued during the period new issue value													$ 1
Sale of stock stated value per share, description													The Series D Investor also had the option to exchange their Series D Preferred Stock into the securities issued in a Qualified Offering upon consummation of a Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis.
Series B Warrants [Member]
Number of warrants to purchase common stock																				122,269
Warrant exercise price																				$ 70
Series B Warrants [Member] | March 2017 Offering [Member]
Number of warrants to purchase common stock														122,269
Warrant exercise price														$ 70
Series C Warrants [Member] | March 2017 Offering [Member]
Number of warrants to purchase common stock														122,269
Gross proceeds from offering, cost percentage														3.00%
Redeemable Preferred Shares [Member]
Fair value of embedded derivative													$ 934
Series D Convertible Preferred Stock [Member]
Convertible preferred stock shares issued upon conversion																					206,105
Shares issued during the period new issue												8,295									8,295
Series B Convertible Preferred Stock [Member]
Percentage of cumulative dividend rate																				15.00%
Fair value of embedded derivative																					$ 0
Series B Convertible Preferred Stock [Member] | Redemption Obligation [Member] | Maximum [Member]
Number of preferred shares converted into common stock												$ 0									$ 274
Series B Convertible Preferred Stock [Member] | Qualified Offering [Member]
Sale of stock stated value per share, description			Series B Convertible Preferred Stock into securities issued in a Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis upon a Qualified Offering.
Series B Preferred Stock [Member]
Preferred stock, shares outstanding																				17,303			17,303
Convertible preferred stock shares issued upon conversion																		111,443					2,759,829
Convertible preferred stock conversion price per share																							$ 0.30
Conversion stock shares converted	[1]																			3,330,828
Series B Preferred Stock [Member] | March 2018 Offering [Member]
Preferred stock, shares outstanding							17,303
Convertible preferred stock shares issued upon conversion							190,333
Convertible preferred stock conversion price per share							$ 3
Series B Preferred Stock [Member] | April 2018 Offering [Member]
Preferred stock, shares outstanding						17,303
Convertible preferred stock shares issued upon conversion						237,916
Convertible preferred stock conversion price per share						$ 1.75
Series D Preferred Stock [Member]
Preferred stock, shares outstanding					300
Convertible preferred stock shares issued upon conversion					71,429
Convertible preferred stock conversion price per share					$ 1.75
Preferred stock description					The fair value increased substantially, i.e by more than 10%, the change in terms was accounted for as an extinguishment.		The fair value increased substantially, i.e by more than 10%, the change in terms was accounted for as an extinguishment.
Changes in carrying amount					$ 32		$ 49
Accretion of the redeemable preferred shares
Number of redeemable preferred stock																				750
Series D Preferred Stock [Member] | SPA Amendment and Waiver Agreement [Member]
Convertible preferred stock conversion price per share					$ 3		$ 7
Offering description							15% of the gross proceeds from the offering
Payments to acquire shares							$ 450
Number of shares purchased							450
Series D Preferred Stock [Member] | March 2018 Offering [Member]
Preferred stock, shares outstanding							750
Convertible preferred stock shares issued upon conversion							142,857
Convertible preferred stock conversion price per share							$ 3
Series D Preferred Stock [Member] | July 2018 Offering [Member]
Number of redeemable preferred stock		300
Series C Preferred Stock [Member]
Preferred stock, shares outstanding																				61,423			378,840
Convertible preferred stock shares issued upon conversion																							6,696,448
Convertible preferred stock conversion price per share																							$ 0.30
Conversion stock shares converted																				1,310,357
Series C Preferred Stock [Member] | Series D Purchase Agreement [Member] | Series D Investor [Member]
Conversion stock shares converted					46,875
Series C Preferred Stock [Member] | Second Waiver Agreement [Member] | Series D Investor [Member] | Planned April 2018 Offering [Member]
Gross proceeds from offering, cost						$ 5,000
Offering description						(i) the Series D Exchange Right would not be applicable to a subsequent financing consisting solely of shares of common stock, which shall be publicly registered on Form S-3 for gross proceeds to us of up to $5,000,000, to be consummated by not later than April 3, 2018 (the Planned April 2018 Offering), (ii) the Company's obligation to use 15% of the proceeds from any subsequent offering of our securities that is not a Qualified Offering to redeem the outstanding shares of the Series C Preferred Stock held by the Series D Investor would not be applicable to the Planned April 2018 Offering, (iii) the Company shall reduce the conversion price of the Series D Preferred Stock to the public offering price of our common stock sold in the Planned April 2018 Offering, and (iv) the Company shall use $300,000 of the proceeds from the Planned April 2018 Offering to redeem outstanding shares of Series C Preferred Stock held by the Series D Investor at a per share purchase price equal to the stated value of the Series C Preferred Stock.
Amount utilized for redemption of outstanding shares						$ 300
Series C Preferred Stock [Member] | March 2018 Offering [Member]
Preferred stock, shares outstanding							741,651
Convertible preferred stock shares issued upon conversion							1,497,427
Convertible preferred stock conversion price per share							$ 3
Series C Preferred Stock [Member] | April 2018 Offering [Member]
Preferred stock, shares outstanding						451,695
Convertible preferred stock shares issued upon conversion						688,297
Convertible preferred stock conversion price per share						$ 1.75
Series C Preferred Stock [Member] | July 2018 Offering [Member]
Number of redeemable preferred stock		306,917
Restricted Stock [Member] | Employees and Directors [Member]
Stock option granted																				0	84
Stock option vesting period																				3 years	3 years
Fair value of stock option																				$ 3	$ 3
Restricted Stock [Member] | Chief Executive Officer [Member]
Stock option granted																				0	84
Stock option vesting period																				3 years	3 years
Fair value of stock option																				$ 3	$ 3
[1]	Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company's discretion, but excluding effect of future conversion price adjustment, if any.

Equity - Schedule of Convertibl

Equity - Schedule of Convertible Preferred Shares (Details) - shares		12 Months Ended
		Dec. 31, 2018	Jun. 29, 2018
Class of Stock [Line Items]
Number of underlying common stock		4,641,185
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Number of preferred stock		17,303	17,303
Number of underlying common stock	[1]	3,330,828
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Number of preferred stock		61,423	378,840
Number of underlying common stock		1,310,357
[1]	Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company's discretion, but excluding effect of future conversion price adjustment, if any.

Equity - Schedule of Converti_2

Equity - Schedule of Convertible Preferred Shares (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2018
Series B Convertible Preferred Stock [Member]
Cumulative dividend rate	15.00%

Equity - Schedule of Issuance o

Equity - Schedule of Issuance of Warrants to Purchase Common Stock (Details)	Dec. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Total Warrants | shares	40,746,189
Weighted average exercise price | $ / shares	$ 1.25
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	52,165
Weighted average exercise price | $ / shares	$ 175
Series B Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	122,269
Weighted average exercise price | $ / shares	$ 70
Series D Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	40,333,332
Weighted average exercise price | $ / shares	$ 0.30
Other Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants | shares	238,423
Weighted average exercise price | $ / shares	$ 88.47

Equity - Schedule of Warrants a

Equity - Schedule of Warrants and Share Options (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee [Member]
Number of Options Outstanding - Beginning of Period	8,167	9,655
Number of Options Granted		118
Number of Options Forfeited	(1,808)	(1,606)
Number of Options Exercised
Number of Options Outstanding - End of Period	6,359	8,167
Number of Options Exercisable at the End of the Period	5,111	5,295
Weighted Average Exercise Price Outstanding - Beginning of Period	$ 970.55	$ 891.8
Weighted Average Exercise Price Granted		32.2
Weighted Average Exercise Price Forfeited	628.62	414.05
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Outstanding - End of Period	$ 1,158.55	$ 970.55
Weighted Average Exercise Price Exercisable at the End of the Period	1,414.42	1,431.85
Non Employee [Member]
Number of Options Outstanding - Beginning of Period	49	61
Number of Options Granted
Number of Options Forfeited	(19)	(12)
Number of Options Exercised
Number of Options Outstanding - End of Period	30	49
Number of Options Exercisable at the End of the Period	28	31
Weighted Average Exercise Price Outstanding - Beginning of Period	$ 21,238.7	$ 31,164.7
Weighted Average Exercise Price Granted
Weighted Average Exercise Price Forfeited	12,471.53	58,165.8
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Outstanding - End of Period	$ 32,348.23	$ 21,238.7
Weighted Average Exercise Price Exercisable at the End of the Period	31,578.81	20,874.35

Equity - Schedule of Informatio

Equity - Schedule of Information About Restricted Shares to Employees (Details) - Employee [Member] - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Outstanding	1,093	3,755
Number of shares Granted		84
Number of shares Forfeited	(201)	(202)
Number of shares Vested	(486)	(2,544)
Number of Shares Outstanding	406	1,093

Equity - Schedule of Warrants_2

Equity - Schedule of Warrants and Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of Shares Outstanding	6,389
Weighted average contractual term	7 years 7 months 13 days
Number of Options Exercisable at the End of the Period	5,138
Exercise Price One [Member]
Exercise price lower limit | $ / shares	$ 0
Exercise price upper limit | $ / shares	$ 65.1
Number of Shares Outstanding	127
Weighted average contractual term	7 years 8 months 5 days
Number of Options Exercisable at the End of the Period	48
Exercise Price Two [Member]
Exercise price lower limit | $ / shares	$ 106.4
Exercise price upper limit | $ / shares	$ 113.75
Number of Shares Outstanding	3,003
Weighted average contractual term	7 years 11 months 1 day
Number of Options Exercisable at the End of the Period	2,002
Exercise Price Three [Member]
Exercise price lower limit | $ / shares	$ 166.25
Exercise price upper limit | $ / shares	$ 437.5
Number of Shares Outstanding	3,051
Weighted average contractual term	7 years 6 months 21 days
Number of Options Exercisable at the End of the Period	2,883
Exercise Price Four [Member]
Exercise price lower limit | $ / shares	$ 1,180
Exercise price upper limit | $ / shares	$ 19,512.5
Number of Shares Outstanding	86
Weighted average contractual term	6 years 6 months 14 days
Number of Options Exercisable at the End of the Period	86
Exercise Price Five [Member]
Exercise price lower limit | $ / shares	$ 25,550
Exercise price upper limit | $ / shares	$ 73,500
Number of Shares Outstanding	122
Weighted average contractual term	2 years 7 months 6 days
Number of Options Exercisable at the End of the Period	119

Equity - Schedule of Assumption

Equity - Schedule of Assumptions Used in Fair Value of Options Granted to Employees (Details)	12 Months Ended
	Dec. 31, 2017
Dividend yield	0.00%
Minimum [Member]
Expected life	5 years
Risk-free interest rates	1.78%
Volatility	94.42%
Maximum [Member]
Expected life	6 years 6 months
Risk-free interest rates	2.18%
Volatility	97.62%

Equity - Schedule of Allocation

Equity - Schedule of Allocation of Total Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total share-based compensation expense	$ 70	$ 672
Cost of Revenues [Member]
Total share-based compensation expense	4	7
Research and Development [Member]
Total share-based compensation expense		32
Selling and Marketing [Member]
Total share-based compensation expense	6	86
General And Administrative Expense [Member]
Total share-based compensation expense	$ 60	$ 547

Taxes on Income (Details Narrat

Taxes on Income (Details Narrative) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2016	Jan. 31, 2016	Dec. 31, 2018	Dec. 31, 2017
Federal corporate tax rate			21.00%
Tax rate on income of beneficiary enterprises			20.00%
Net carry forward tax loss			$ 71,000
Net loss carryforwards percentage			80.00%
Israel Tax Authority [Member]
Federal corporate tax rate	25.00%	26.50%	23.00%	24.00%
Revised corporate tax rate	23.00%	25.00%
Revised tax rate on income of preferred enterprises			10.00%
Tax rate on income of beneficiary enterprises			23.00%
Net carry forward tax loss			$ 40,000
Israel Tax Authority [Member] | 2018 and Thereafter [Member]
Federal corporate tax rate			23.00%
Israel Tax Authority [Member] | Arising Before January 1, 2018 [Member]
Net carry forward tax loss			$ 36,000
Operating loss carryforwards expiration description			expires until 2037
Israel Tax Authority [Member] | Limited [Member]
Net carry forward tax loss			$ 4,000
Germany [Member]
Federal corporate tax rate			15.825%
Corporate trade tax rate			17.15%

Taxes on Income - Schedule of C

Taxes on Income - Schedule of Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss before taxes on income	$ (7,240)	$ (8,411)
Parent Company [Member]
Loss before taxes on income	(2,884)	(3,673)
Subsidiaries [Member]
Loss before taxes on income	$ (4,356)	$ (4,738)

Taxes on Income - Schedule of_2

Taxes on Income - Schedule of Changes in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 27,240	$ 29,682
Changes following enactment of the Act		(5,879)
Losses during the year (including foreign exchange rate effect)	400	3,437
Balance at the end of the year	$ 27,640	$ 27,240

Taxes on Income - Schedule of R

Taxes on Income - Schedule of Reconciliation of Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Uncertain tax positions balance at beginning of period
Increase in uncertain tax positions because of tax positions taken during the year		$ 28
Uncertain tax positions balance at end of period	$ 28

Taxes on Income - Schedule of O

Taxes on Income - Schedule of Open Tax Years by Major Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2018
U.S. [Member] | Earliest Tax Year [Member]
Open Tax Year	2,015
U.S. [Member] | Latest Tax Year [Member]
Open Tax Year	2,018
Israel [Member] | Earliest Tax Year [Member]
Open Tax Year	2,014
Israel [Member] | Latest Tax Year [Member]
Open Tax Year	2,018
Germany [Member] | Earliest Tax Year [Member]
Open Tax Year	2,013
Germany [Member] | Latest Tax Year [Member]
Open Tax Year	2,018
United Kingdom [Member] | Earliest Tax Year [Member]
Open Tax Year	2,014
United Kingdom [Member] | Latest Tax Year [Member]
Open Tax Year	2,015

Taxes on Income - Schedule of D

Taxes on Income - Schedule of Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Allowance for doubtful accounts	$ 3	$ 3
Allowance for bonus		54
Provision for vacation and recreation pay	38	37
R&D expenses	339	289
Share-based compensation	2,581	2,577
Carry forward tax losses	24,643	24,245
Accrued severance pay, net	36	35
Deferred tax assets noncurrent	27,640	27,240
Less-valuation allowance	(27,640)	(27,240)	$ (29,682)
Deferred tax assets

Supplementary Financial State_3

Supplementary Financial Statement Information - Schedule of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance at beginning of period		$ 336
Additions during the period
Bad debt written-off during the period		(270)
Exchange rate differences		$ 6
Balance at end of period	$ 72

Supplementary Financial State_4

Supplementary Financial Statement Information - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 284	$ 174
Work in process	111	63
Raw materials and supplies	739	296
Total inventories	$ 1,134	$ 533

Supplementary Financial State_5

Supplementary Financial Statement Information - Schedule of Accounts Payable and Accruals - Other (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 828	$ 853
Accrued vacation and recreation pay	171	165
Accrued expenses	903	976
Provision for sales commissions	37	109
Other	27	31
Total accounts payable and accruals-other	$ 1,966	$ 2,134

Disaggregated Revenue and Ent_3

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 3,601	$ 2,761
Germany [Member]
Revenues	855	551
Italy [Member]
Revenues	632	557
Russia [Member]
Revenues	351	343
Other [Member]
Revenues	$ 1,763	$ 1,310

Disaggregated Revenue and Ent_4

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 3,601	$ 2,761
CGuard™ EPS [Member]
Segment Reporting Information [Line Items]
Revenue	2,970	1,922
MGuard Prime™ EPS [Member]
Segment Reporting Information [Line Items]
Revenue	$ 631	$ 839

Disaggregated Revenue and Ent_5

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Principal Customers (Details) - Sales [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Customer A [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	22.00%	14.00%
Customer B [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	10.00%	12.00%
Customer C [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	10.00%	12.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	Feb. 28, 2019	Feb. 04, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted stock, shares			201	202
Severance payment			$ 186	$ 154
Subsequent Event [Member]
Restricted stock, shares		2,000,000
Restricted common stock shares percentage		5.00%
Shares outstanding granted		2,000,000
Severance payment		$ 850
Subsequent Event [Member] | Employees and Directors [Member]
Restricted stock, shares	3,437,275
Subsequent Event [Member] | A&R Employment Agreement [Member]
Severance payment	$ 33	$ 600
Subsequent Event [Member] | Stock Option [Member]
Restricted common stock shares percentage		50.00%
Subsequent Event [Member] | Restricted Stock [Member]
Restricted common stock shares percentage		50.00%